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Background: The potential role of growth factors in chronic obstructive pulmonary disease 
(COPD) has begun to be addressed only recently and is still poorly understood. For this study, 
we investigated potential abnormalities of hepatocyte growth factor (HGF) and keratinocyte 
growth factor (KGF) in patients with COPD.
Methods: To this end, we compared the levels of HGF and KGF, measured by enzyme-linked 
immunosorbent assay (ELISA), in bronchoalveolar lavage (BAL) ﬂ  uid and in serum in 18 patients 
with COPD (62 ± 9 yrs, forced expiratory volume in one second [FEV1] 57 ± 12% ref, X ± standard 
deviation of mean), 18 smokers with normal lung function (58 ± 8 yrs, FEV1 90 ± 6% ref) and 
8 never smokers (67 ± 9 yrs, 94 ± 14% ref).
Results: We found that in BAL, HGF levels were higher in patients with COPD than in the 
other two groups whereas, in serum, HGF concentration was highest in smokers with normal 
lung function (p  0.01). KGF levels were not signiﬁ  cantly different between groups, neither 
in blood nor in BAL (most values were below the detection limit).
Conclusions: These results highlight a different response of HGF in BAL and serum in smokers 
with and without COPD that may be relevant for tissue repair in COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by extensive lung 
damage, which is believed to result from the abnormal inﬂ  ammatory response that 
occurs in the so-called susceptible smokers in response to inhaled particles and gases, 
mostly, tobacco smoking (Rabe et al 2007). The potential role of repair processes in 
COPD has begun to be addressed only recently and is still poorly understood.
Growth factors are key controllers of repair. In the lungs, hepatocyte growth factor 
(HGF) and keratinocyte growth factor (KGF), also known as ﬁ  broblast growth factor-7, 
are particularly relevant due to their capacity to stimulate alveolar and bronchial epi-
thelial cell proliferation (Mason 2002; Bonay et al 2005). HGF is a multifunctional 
heterodimeric protein with mitogenic properties that is synthesized by a variety of lung 
cell types, including ﬁ  broblasts, macrophages, smooth muscle cells and epithelial cells 
(Mason 2002). In humans, HGF expression increases in serum after pneumonectomy 
(Sugahara et al 1998) and acute lung injury (ALI) (Stern et al 2000). In experimental 
animals in vivo gene transfection of HGF ameliorates pulmonary emphysema (Shige-
mura et al 2005) and drug-induced pulmonary injury (Dohi et al 2000). On the other 
hand, KGF is a heparin-binding mitogen secreted primarily by ﬁ  broblasts (Ulich et al 
1994) and T lymphocytes (Boismenu et al 1994). Like HGF, KGF increases after 
lung injury in humans (Stern et al 2000) and minimizes lung injury in experimental 
animals (Welsh et al 2000).International Journal of COPD 2008:3(4) 720
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The role of HGF and KGF in COPD has been addressed 
by two previous studies. Plantier and colleagues (2005) 
found that cultured ﬁ  broblasts harvested from patients with 
emphysema produced less HGF (but similar amounts of 
KGF) than controls, and Bonay and colleagues (2005) found a 
direct relationship between the severity of airﬂ  ow obstruction 
and HGF mRNA content in lung samples of smokers. These 
two studies suggest, therefore, that the pulmonary regulation 
of HGF may be abnormal in patients with COPD. However, 
both HGF and KGF can also be released by extrapulmonary 
organs, thus having the potential to act systemically 
(Verghese et al 1998; Sekine et al 2004). Given the current 
clinical relevance attributed to the systemic effects of COPD 
(Agusti et al 2003), in this study we compared the levels of 
HGF and KGF in the pulmonary (bronchoalveolar lavage 
[BAL] ﬂ  uid) and systemic compartment (circulating blood) 
of smokers with and without COPD and never smokers.
Methods
Subjects and ethics
We studied 18 patients with COPD (GOLD II–III) (Rabe et al 
2007), 18 smokers without chronic bronchitis or dyspnea and 
with normal lung function, and 8 never smokers. All of them 
required bronchoscopy for clinical purposes mainly to evaluate a 
solitary pulmonary nodule or a hemoptysis episode in the group 
of patients with COPD and smokers with normal lung function. 
The percentage of lung neoplasms was similar in both groups. 
In the never smoker group, the main indication was hemoptysis 
or chronic cough. All patients with COPD had not had any 
exacerbation for at least the three months that preceded their 
inclusion in the study. All of them were treated with inhaled 
bronchodilators (salmeterol, salbutamol, ipratropium bromide, 
and/or tiotropium); 4 patients also received inhaled cortico-
steroids (ICS), but none received oral steroids. We excluded 
patients with other chronic lung diseases (asthma, bronchiectasis, 
and interstitial lung diseases) and cardiac, hepatic, or renal 
failure. All participants signed an informed consent. The Ethics 
Committee of our institution approved the study protocol.
Lung function
A forced spirometry (GS, Warren E. Collins, Braintree, 
MA, USA) was obtained in all participants (ATS 1995). 
Spirometric reference values were those of a Mediterranean 
population (Roca et al 1986).
Blood analysis
A peripheral venous blood sample (10 cc) was obtained 
before bronchoscopy by venipuncture from an ante-cubital 
vein. Samples were immediately centrifuged at 1200 g 
during 10 minutes. Thereafter, serum samples were frozen 
in aliquots at −80 °C until analysis. All serum samples were 
processed identically and analyzed simultaneously at the 
completion of the study.
Bronchoscopy
Bronchoscopy was performed with a ﬂ  exible ﬁ  beroptic 
bronchoscope (Pentax 15v, Tokyo, Japan). Active smok-
ers were requested to refrain from smoking for at least 
12 hours before bronchoscopy. This was checked by the 
exhaled carbon monoxide (CO) concentration (ToxCO, 
Bedfont, UK), which was lower than 10 ppm in all 
participants. BAL was performed following the standard 
methodology (Pons et al 2005). In brief, we instilled eight 
25 mL aliquots (n = 8) of sterile saline solution in one 
pulmonary segment of one of the middle lobe or lingula not 
containing any visible lung nodule or inﬁ  ltrate. Aliquots 
were placed in plastic recipients and immediately centri-
fuged at 200 × g for 10 min (at 4 °C), and the supernatant 
was stored at −80 °C until analysis.
We excluded the presence of airway bacterial infection 
by using a protected specimen brush (PSB) (Mill-Rose Lab, 
Mentor OH, USA) to sample bronchial secretions before 
BAL (Wimberley et al 1982). The culture of PBS samples 
yielded less than 103 CFU/mL in all participants.
Measurement of HGF and KGF
The concentration of HGF and KGF in BAL supernatant 
and serum was measured using a commercially available 
sandwich enzyme-linked immunosorbent assay (ELISA) 
kits (Amersham Pharmacia Biotech UK Ltd, Bucks, UK) 
following the manufacturer´s directions (Amersham 
Pharmacia Biotech UK Ltd). The detection limits of HGF 
and KGF were 40 pg/ml and 15 pg/ml respectively. HGF 
and KGF concentrations were corrected for the albumin 
concentration in BAL like in previous studies (Sakai et al 
1997).
Statistical analysis
Demographic are expressed as mean ± standard deviation 
(SD) and biological data as median and range values. One 
way analysis of variance (ANOVA), followed by post-hoc 
contrast (Scheffe test) if appropriate, was used to assess the 
statistical signiﬁ  cance of the differences between groups. 
Correlations between variables of interest were explored using 
the Spearman test. A p value lower than 0.05 was considered 
signiﬁ  cant.International Journal of COPD 2008:3(4) 721
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Results
Anthropometric and functional data
Table 1 presents the main clinical and lung function data of 
all participants. Age was similar in the three groups. Smok-
ing exposure was higher in patients with COPD (Table 1). 
On average patients with COPD showed moderate airﬂ  ow 
obstruction whereas, by deﬁ  nition, spirometry was normal in 
smokers with normal lung function and never smokers.
BAL cell count
Total cell count was higher in smokers with normal lung 
function 2 × 105/mL [0.4–7] than in nonsmokers (0.5 × 105/mL 
[0.4–1], p  0.05). Patients with COPD also showed a 
trend towards higher values (1.1 × 105/mL [0.5–3.3]) but 
differences failed to reach statistical signiﬁ  cance. Differential 
cell counts were similar among groups (Table 2).
HGF and KGF concentrations
The concentration of HGF (corrected for albumin, HGF/
albumin) in BAL was signiﬁ  cantly higher in patients with 
COPD (62 pg/mg of albumin [13–184], p  0.01) than in 
smokers with normal lung function (6.3 pg/mg of albumin 
[1–14]) and never smokers (14 pg/mg of albumin [4–25]) 
(Figure 1). There were no signiﬁ  cant differences in albu-
min concentration in BAL in all groups: COPD, 21 mg/ml 
(7.6–44.3); Smokers 19 mg/ml (9–38 mg/ml); and, never 
smokers 11 mg/ml (7–16). In contrast, the serum concentra-
tion of HGF was higher (p  0.01) in smokers with normal 
lung function (1897 pg/ml [433–2692]) than in patients 
with COPD (1053 pg/ml [629–1630]) and never smokers 
(700 pg/ml [424–986]) (Figure 2).
The concentration of KGF in BAL was undetectable in most 
individuals. Likewise, 9 patients with COPD and 9 smokers 
with normal lung function showed undetectable levels of KGF 
in their serum. In the remaining participants, KGF levels were 
70  pg/ml (27–553) (COPD) and 463 pg/ml (32–621) (smokers) 
(p = 0.09). All nonsmokers showed undetectable values.
Effect of inhaled corticosteroids
Only four patients with COPD were receiving therapy with 
ICS, and results did not change after removing them from 
the analysis.
Effect of smoking
As mentioned in methods, all current smokers (irrespective 
of the presence or absence of airﬂ  ow obstruction) refrained 
from smoking for at least 12 hours before bronchoscopy. In 
patients with COPD we compared the levels of HGF and 
KGF in current smokers (n = 6) and exsmokers (n = 12), 
but we were unable to ﬁ  nd any signiﬁ  cant difference in 
HGF levels (BAL, 62 pg/mg albumin [13–156] vs. 58 pg/mg 
albumin (15–184); serum, 1057 pg/ml (629–1406) vs 1057 
pg/ml (703–1629), respectively). Due to the small number of 
patients with detectable levels of KGF, we could not compare 
KGF values in these two subgroups of subjects.
Physiological correlates
We explored potential relationships between HGF and KGF 
levels and several variables of interest, such as age, body 
mass index, severity of airﬂ  ow obstruction and total and dif-
ferential cell counts of the BAL but were not able to ﬁ  nd any 
signiﬁ  cant relationship. There were no signiﬁ  cant relation-
ships between BAL and plasma HGF or KGF concentrations. 
Likewise, because patients with COPD had a higher smoking 
exposure we investigated the potential correlation between 
the latter (pack-yrs) and growth factor concentrations but 
were unable to ﬁ  nd them.
Discussion
This study compares the pulmonary and systemic concen-
trations of two key lung growth factors (HGF and KGF) in 
patients with COPD, smokers with normal lung function and 
never smokers. We found that HGF levels were signiﬁ  cantly 
increased in BAL in patients with COPD, and in serum in smok-
ers with normal lung function (Figures 1 and 2). In contrast 
Table 1 Clinical and lung function data (mean ± SD) of all participants
Nonsmokers (n = 8) Smokers with normal 
lung function (n = 18)
COPD (n = 18)
Age (yr.) 67 ± 9 58 ± 8 62 ± 7
Pack-yr. 0 37 ± 14a 48 ± 15ab
FEV1 (% predicted) 94 ± 14 90 ± 6 57 ± 12ab
FEV1/FVC (%) 80 ± 6 76 ± 5 54 ± 8ab
Notes: ap  0.01 (vs nonsmokers); bp  0.05 (vs smokers with normal lung function).
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; SD, standard deviation.International Journal of COPD 2008:3(4) 722
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we were not able to ﬁ  nd signiﬁ  cant differences in KGF levels 
between these three groups, neither in blood nor in BAL.
To our knowledge this is the ﬁ  rst study that evaluates 
HGF and KGF levels in BAL and serum in patients with 
COPD. Two previous studies however have investigated 
the potential role of HGF and KGF in these patients. Plan-
tier and colleagues (2005) found that ﬁ  broblasts harvested 
from patients with pulmonary emphysema produced in vitro 
less HGF but similar KGF levels than healthy smokers and 
nonsmokers. This may seem at variance with our results. Two 
factors can contribute to explain this apparent discrepancy. 
First, they studied in vitro the response of a speciﬁ  c cell type 
(the ﬁ  broblast) whereas we studied in vivo the end result of a 
variety of cell types. Second, they studied patients with very 
severe COPD who required lung volume reduction surgery 
or lung transplantation, whereas we studied patients with, 
mostly, moderate disease. In contrast, the second study by 
Bonay and colleagues (2005) reported a direct relationship 
Table 2 Bronchoalveolar lavage ﬂ  uid total and differential cell counts (Median and range)
Nonsmokers (n = 8) Smokers with normal lung 
function (n = 18)
COPD (n = 18)
Total cell count (x105/mL) 0.5 (0.4–1) 2 (0.4–7)* 1.1 (0.5–3.3)
Macrophages (%) 91 (87–93) 97 (77–98) 90 (65–99)
Lymphocytes (%) 9 (4–13) 3 (0–20) 9 (1–25)
Neutrophils (%) 0 (0–3) 1 (0–3) 1 (0–10)
Notes: *p  0.05 vs nonsmokers.
Abbreviation: COPD, chronic obstructive pulmonary disease.
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Figure 1 HGF concentration in BAL in the three groups of individuals studied.
Abbreviations: BAL, bronchoalveolar lavage; HGF, hepatocyte growth factor.International Journal of COPD 2008:3(4) 723
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between the degree of airﬂ  ow obstruction and HGF mRNA in 
lung tissue of smokers with and without COPD, which seem 
to agree with the results of our study (Figure 1). Interest-
ingly, other growth factors, such as ﬁ  broblast growth factor 
(FGF) −1 and −2 appear also to be increased in bronchial 
airway wall (Kranenburg et al 2005) and placental growth 
factor in BAL in patients with COPD (Cheng et al 2008). 
Therefore, the results of our study in combination with other 
previous ones (Bonay et al 2005; Kranenburg et al 2005; 
Cheng et al 2008) seem to indicate that a variety of growth 
factors are upregulated in the lungs of patients with COPD. 
In principle, this is consistent with an active repair response. 
Yet, lung function deteriorates rapidly in COPD, indicating 
that this response may not fully effective. This is not the 
case in other conditions characterized by lung injury, such 
as acute respiratory distress syndrome (Stern et al 2000), 
pneumonia (Amano et al 2004), and ventilation induced lung 
injury (Welsh et al 2000), where a similar HGF response has 
been described. It is possible that differences are related to 
the chronic and repetitive nature of tissue injury in COPD 
(mostly tobacco smoking). However, given that the levels 
of HGF in BAL were not different in active smokers and 
ex-smokers with COPD, we hypothesize that lung repair 
may be insufﬁ  cient or inadequate in COPD.
Previous published studies have shown a relationship 
between HGF and neutrophil count in BAL ﬂ  uid in different 
pulmonary diseases, suggesting that alveolar neutrophils 
play a major role in HGF production in the lung (Sakai et al 
1997; Jaffre et al 2002). In contrast, we did not ﬁ  nd such a 
correlation. This discrepancy could be due to the fact that 
previous studies evaluated different diseases (with different 
pathogeny) such as acute respiratory failure (Jaffre et al 2002) 
and interstitial lung disease (Sakai et al 1997). It is likely that 
the response to lung injury in COPD may be different (Barnes 
2004) and include activated cells, cytokines, and oxidative 
stress that were not measured in the present study.
Studies in control subjects were unable to detect HGF in 
BAL ﬂ  uid or its concentration was very low (Yamanouchi 
et al 1998; Stern et al 2000). This is also at variance with 
our results, because our controls were not healthy individu-
als and patients that required a bronchoscopy for a variety 
of clinical reasons.
Because COPD has a systemic component (Agusti 
et al 2003), and both HGF and KGF are also secreted by 
Figure 2 HGF concentration in serum in the three groups of individuals studied.
Abbreviation: HGF, hepatocyte growth factor.
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extrapulmonary cells (Mason 2002; Steiling et al 2004), 
it was also of interest to to analyze their concentration in 
serum. Previous investigations have reported that serum HGF 
levels increase after pneumonectomy (Sugahara et al 1998), 
smoking (Chen et al 2006) and in several acute and chronic 
disorders such as liver, kidney, and cardiovascular disease 
(Borawski et al 2002; Ozden et al 2004). More recently, 
Palange and colleagues (2006) found increased HGF serum 
concentrations in patients with COPD compared to never 
smokers. This latter observation fully agrees with our results, 
albeit we extend their observations to include smokers with 
normal lung function (Table 1). Like Palange and colleagues 
(2006) we found that HGF serum levels were higher in COPD 
patients than in never smokers, but this increase was much 
enhanced in smokers with normal lung function (Figure 2). 
This may suggest a blunted systemic response that may 
potentially limit lung repair. Alternatively, a decreased sys-
temic level of HGF compared to smokers with normal lung 
function may also reﬂ  ect increased consumption in the lungs 
of patients with COPD. In contrast to HGF ﬁ  ndings, we do 
not ﬁ  nd signiﬁ  cant differences in KGF levels between groups, 
neither in BAL or blood, because most values were below the 
detection limit of the technique. We do not think that this is 
due to technical reasons because we used same methodology 
used in previous (Plantier et al 2005). Alternatively, given 
that the three groups of subjects studied showed very low 
KGF levels, this may indicate that KGF is not involved in the 
pathogenesis of smoking related diseases, at variance with 
other disease states like ALI (Verghese et al 1998).
Several methodological aspects of our study deserve 
comment. First, because it is known that smoking increases 
HGF (Chen et al 2006), we conﬁ  rmed that participants refrained 
from smoking 12 hours before bronchoscopy by measuring 
the exhaled CO concentration (which was lower than 10 ppm 
in all participants). Second, albeit patients with COPD had 
higher smoking exposure that smokers with normal lung func-
tion we do not believe that this inﬂ  uenced our results because 
we did not ﬁ  nd any correlation between smoking exposure 
(pack-yrs) and levels of growth factors. Third, in patients with 
lung cancer, an overexpression of HGF in lung tissue close to 
the tumor has been reported (Chen et al 2006). Yet, we think 
that this did not biased our results because we studied patients 
with Stage I lung cancer in whom the over expression of HGF 
is negligible ( Chen et al 2006), BAL was always performed 
in the lung without chest X-ray anomalies and HGF levels 
were not different in smokers with and without cancer. Fourth, 
although steroids can modulate the concentration of growth 
factors (Blanquaert et al 2000), results were unchanged after 
excluding the 4 patients treated with ICS. Likewise, although 
infection can also inﬂ  uence growth factor concentration (Nayeri 
et al 2002), we excluded this potential confounding effect on 
the basis of negative cultures of PBS samples.
Conclusion
Our study reports that the levels of HGF (but not those of 
KGF) in BAL ﬂ  uid were higher in patients with COPD than 
in smokers with normal lung function or never smokers. 
Interestingly, these results were not mirrored in the systemic 
circulation, where only smokers with normal lung function 
(but not patients with COPD) were able to mount a vigorous 
HGF response. Overall, these results address a still poorly 
understood but potentially very relevant area of repair in 
COPD, the true therapeutic holy grail in this devastating and 
progressive disease.
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